Analogic names Miller CEO
Analogic has a new leader, and it’s a familiar name to medical imaging industry veterans. Longtime Siemens employee Thomas Miller will be joining the Peabody, MA-based firm as president and CEO in October. Miller has most recently served as
Analogic has a new leader, and its a familiar name to medical imaging industry veterans. Longtime Siemens employee Thomas Miller will be joining the Peabody, MA-based firm as president and CEO in October. Miller has most recently served as president and CEO at Carl Zeiss of Thornwood, NY, as well as world general manager of Carl Zeiss Medical Group in Oberkochen, Germany. Before his stint at Carl Zeiss, Miller was group vice president, imaging systems, for Siemens Medical Systems in North America, and general manager for Siemens MRI division in Erlangen, Germany.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
